Equity Overview
Price & Market Data
Price: $0.026
Daily Change: -$0.006 / 23.08%
Range: $0.0234 - $0.032
Market Cap: $973,515
Volume: 306,799
Performance Metrics
1 Week: 43.14%
1 Month: -34.02%
3 Months: -85.97%
6 Months: -98.61%
1 Year: -99.45%
YTD: -87.93%
Company Details
Employees: 68
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.